The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

What Was Tested

This randomized controlled trial looks at Vitamin D in the context of hyperparathyroidism.

Current treatment of secondary hyperparathyroidism in chronic kidney failure with calcium and active vitamin D is potentially limited by hypercalcemia and hyperphosphatemia.

Changes in plasma PTH, serum calcium, serum phosphorus, and calcium x phosphorus levels were compared between AMG 073 and placebo groups.

Who Took Part

The abstract describes 073 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Vitamin D study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Vitamin D could be set against what happens without it.

What Was Measured

Current treatment of secondary hyperparathyroidism in chronic kidney failure with calcium and active vitamin D is potentially limited by hypercalcemia and hyperphosphatemia.

Changes in plasma PTH, serum calcium, serum phosphorus, and calcium x phosphorus levels were compared between AMG 073 and placebo groups.

PubMed files the paper under topics including Calcium, Cinacalcet, Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Naphthalenes, Parathyroid Hormone and Phosphorus.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D in 073 patients in people with hyperparathyroidism.

The publication is from 2003 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: the related Vitamin D, K2, Magnesium and Zinc library page, Hyperparathyroidism research.